Dermatologic Implications of Glycemic Control Medications for Patients with Type 2 Diabetes Mellitus
Mayra Betancourt Ponce1, Bridget E Shields1
1University of Wisconsin School of Medicine and Public Health, Madison. Dr. Shields also is from the Department of Dermatology.
Abstract:
Type 2 diabetes mellitus (T2DM) is a chronic disease with a rising prevalence worldwide that is characterized by hyperglycemia and insulin resistance. Metformin, which improves blood glucose levels and insulin sensitivity, is considered the first-line therapy for T2DM. In patients with T2DM who are overweight or obese, glucagonlike peptide 1 (GLP-1) and dual GLP-1/gastric inhibitory peptide (GIP) agonists are used as adjunct or alternative therapies given their dual benefits for insulin sensitivity and weight loss. Beyond the metabolic implications of T2DM medications, these agents also have hormonal and immunologic effects that may impact dermatologic diseases (eg, psoriasis, hidradenitis suppurativa [HS]). In this review, we highlight the dermatologic adverse effects and potential therapeutic benefits of metformin as well as GLP-1 and GLP-1/GIP agonists.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Diabetes: Symptoms, Diagnosis, and Complications


